FIELD NOTE
Oura Is Going Public on the Wellness Exemption
Oura filed to go public on September 3, with a planned Nasdaq listing under OURA and Goldman Sachs, Morgan Stanley and J.P. Morgan on the cover. The numbers are the kind most device companies never see: $1.21 billion in revenue for the nine months to June 30, up 74%; $974 million of it hardware, $240 million recurring membership; a 55% gross margin; $60.8 million in net income. Paid members doubled in a year to 5.0 million. The Wall Street Journal has reported a valuation north of $11 billion.
Buried in the risk factors is the sentence that matters for this audience. Oura markets its products as general wellness tools it believes are not subject to FDA device requirements. Then it tells investors it expects features it introduces going forward to be regulated as medical devices.
That is not a hedge. It is the plan, and the company has been executing it in the open.
In January the FDA loosened its wellness guidance, giving wearables room to surface trends in measures like blood pressure without crossing into device territory. Oura moved in May: it shipped a nighttime blood pressure trend feature under the wellness exemption, one that deliberately shows no systolic or diastolic numbers, while running a separate IRB-approved study of an algorithm meant to flag hidden hypertension. That second feature is intended to go through FDA. As of June 30, the study had enrolled more than 350,000 participants.
Read that number the way a clinical-stage device company would. Oura recruited a hypertension study population larger than most registries by pushing a notification to people who had already paid $349 to $499 for the sensor and $5.99 a month for the app. Members wear the ring a median of 23 hours a day. Twelve-month paid retention is roughly 85%. The company holds nearly 42 billion hours of longitudinal biometric data. Evidence generation, for Oura, is a feature rollout.
This is the device commercialization sequence run backward. The standard playbook is intended use, then evidence, then clearance, then reimbursement, then a sales force, then scale. Oura built the installed base and the habit first, then the data, and now proposes to buy regulation one feature at a time, only where a cleared claim is worth more than a wellness one. Its partnerships with Dexcom, ResMed and Eli Lilly, which holds a SAFE note converting at the IPO, let it borrow clinical pathways without owning them. ResMed’s deal routes ring users with breathing disturbances toward a clinician, so Oura never has to claim it detects sleep apnea.
The wellness line cuts both ways, though, and the S-1 knows it. A proposed class action in the Northern District of California argues Oura’s sleep-stage accuracy is no better than a coin flip; the prospectus lists accuracy litigation as a standing risk. More than half of members report a chronic condition, and 80% of those say they use Oura data to inform decisions about it. The company presents that as a strength. A regulator reading intended use might not. And once Oura holds a cleared hypertension feature, every accuracy claim on the adjacent wellness features will be read against a clinical standard, whether or not the FDA asks.
There is also the capital structure. The filing shows a $985 million deemed dividend to preferred holders and a $742 million net financing outflow for the period, meaning early investors took substantial liquidity before public buyers arrive. Net income is real; the $924 million net loss attributable to common stockholders is an accounting artifact of that transaction.
For device operators, the uncomfortable takeaway is this. The largest new public company in health hardware this year has never submitted a 510(k), and it is walking into regulation from a position of five million paying users rather than toward it from a position of zero. Clearance-first sequencing is still the safe path for anything that goes inside the body. For anything that sits on it, Oura just filed the case that it may no longer be the fast one.
SPONSORED BY RŌG HEALTH
Most device companies don't fail on technology. They fail on sequencing.
The free Commercial Readiness Check from RŌG Health takes two minutes and scores your commercialization across six dimensions — where you’re strongest, where you’re exposed, and what to fix first. If you want help closing a gap, it’ll point you to the right starting place.
Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.